Literature DB >> 6166367

Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies.

R C Seeger, H M Rosenblatt, K Imai, S Ferrone.   

Abstract

Antigenic determinants that are common to melanomas, gliomas, neuroblastomas, and sarcomas but that are minimally or not detectably expressed by adult tissues were defined with monoclonal antibodies. Quantitative absorption of monoclonal antibody (Ab 165) with adult tissues followed by testing on antigen-positive UCLA-SO-M14 melanoma cells did not demonstrate antigenic determinant (Ag 165) in brain, lung, liver, kidney, intestine, adrenal, and muscle, Absorption of Ab 376 demonstrated Ag 376 in adult lung but minimal or no antigen in other tissues. Both antigens were associated with a variety of fetal tissues. Assessment of 28 human tumor cell lines with the 131I-staphylococcal Protein A-binding test demonstrated that Ab 165 reacted strongly with melanomas and gliomas and weakly with sarcomas. Ab 376 reacted strongly with melanomas, gliomas, neuroblastomas, and sarcomas. Neither of these antibodies reacted appreciably with carcinoma or teratoma cell lines. Absorption of Ab 165 and Ab 376 with noncultured tumors demonstrated that melanomas, sarcomas, and neuroblastomas can have greater quantities of these antigens in vivo than do normal adult tissues. Qualitative and quantitative antigenic heterogeneity within positive classes of tumors was demonstrated for both cultured and noncultured tumors. The differences in antigen expression in vivo between normal and neoplastic cells suggest potential value for these antibodies in immunodiagnosis and possibly immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166367

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Immunobiology of brain tumors.

Authors:  E Frank; N de Tribolet
Journal:  Neurosurg Rev       Date:  1986       Impact factor: 3.042

2.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

Authors:  D D Chi; R E Merchant; R Rand; A J Conrad; D Garrison; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

Review 3.  The immunobiology of human gliomas.

Authors:  V Piguet; A C Diserens; S Carrel; J P Mach; N de Tribolet
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Perineural spread by squamous carcinomas of the head and neck: a morphological study using antiaxonal and antimyelin monoclonal antibodies.

Authors:  R L Carter; C S Foster; E A Dinsdale; M R Pittam
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

Review 5.  Molecular lesions in cancer.

Authors:  H Busch
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

6.  Characterisation of ocular melanoma with cutaneous melanoma antibodies.

Authors:  J Bomanji; A Garner; J Prasad; D M Albert; J L Hungerford; M Granowska; K E Britton
Journal:  Br J Ophthalmol       Date:  1987-09       Impact factor: 4.638

7.  Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen.

Authors:  D Shouval; J R Wands; V R Zurawski; K J Isselbacher; D A Shafritz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

8.  Human melanoma-associated antigen expression on human neuroblastoma cells: effects of differentiation inducers.

Authors:  V Feyles; W T Dixon; L K Sikora; R C McGarry; L M Jerry
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 9.  Immunology of gliomas.

Authors:  N de Tribolet
Journal:  Childs Nerv Syst       Date:  1989-04       Impact factor: 1.475

10.  Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies.

Authors:  J Brüggen; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.